DEAR ALZPROTECT LEADERSHIP TEAM
As the lead Principal Investigator for the upcoming Progressive Supranuclear Palsy (PSP) Trial Platform (PTP), this letter confirm our intent to include Ezeprogind/AZP2006 in the first cycle of this trial. We believe that your drug holds significant potential for the future of the field and therapeutic landscape for this devastating disease. As you are aware, Progressive Supranuclear Palsy (PSP) is a severe neurodegenerative disease of aging that usually leads to death within 5-7 years of diagnosis and there are currently no effective treatments for PSP. New, efficient clinical PSP trial programs and focused efforts to identify PSP biomarkers are urgently needed. The overarching goal of the PSP Trial Platform (PTP) is to conduct a randomized, placebo- controlled, Phase 2 platform trial in mild-moderate PSP that will simultaneously test several therapies to determine safety, tolerability and clinical proof of concept based on a multimodal clinical rating scale, the modified PSP Rating Scale-15 (mPSPRS-15). This innovative NIH-funded project aims to investigate the safety, efficacy, and tolerability of multiple interventions in 440 PSP patients over 50+ clinical sites in the United States and Canada, leveraging a shared placebo group. Given the strong preclinical and clinical results showing reduced tau hyperphosphorylation, combined with clinical demonstration of target engagement based on CSF measurement, suggest that AZP2006 may powerful candidate for treating PSP and the unmet medical need in this patient population, we believe that your compound could offer significant advancements in PSP and are optimistic about the potential outcomes in this trial.
We are very enthusiastic about including Ezeprogind/AZP2006 as one of the platform interventions and will work with you to finalize the regimen details.
Thank you for your ongoing partnership, and we look forward to successfully collaborating on this exciting new chapter of PSP clinical research.
Sincerely,
Adam L. Boxer, MD, PhD Endowed Professor in Memory and Aging UC San Francisco School of Medicine
